title: Voriconazole therapeutic drug monitoring: focus on safety.
abstract: BACKGROUND
  Voriconazole has been widely used for the treatment of invasive fungal diseases, particularly invasive aspergillosis. Drug-drug interactions are, however, the main drawback associated with voriconazole use, since this drug suffers from extensive hepatic metabolism.
  
  
  METHODS
  This article reviews the current literature on voriconazole therapeutic drug monitoring, with a special focus on drug safety.
  
  
  RESULTS
  An update on voriconazole metabolism, drug interactions, toxicity and the relation of these with voriconazole drug concentrations.
  
  
  CONCLUSIONS
  Therapy with voriconazole may be better guided by measuring voriconazole concentrations in the plasma.
authors.affiliation: Universidade Federal do Rio Grande do Sul, Post Graduation Program in Pulmonary Sciences, Porto Alegre, Brazil.
authors.forename: Alessandro C
authors.initials: AC
authors.lastname: Pasqualotto
authors.forename: Melissa O
authors.initials: MO
authors.lastname: Xavier
authors.forename: Huander F
authors.initials: HF
authors.lastname: Andreolla
authors.forename: Rafael
authors.initials: R
authors.lastname: Linden
mesh_terms: D000935:Antifungal Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D019411:Clinical Laboratory Techniques; D065731:Cytochrome P-450 CYP2C19; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects* / Q000235:genetics; D004347:Drug Interactions; D016903:Drug Monitoring; D006801:Humans; D011110:Polymorphism, Genetic; D011743:Pyrimidines / Q000009:adverse effects* / Q000493:pharmacokinetics; D014230:Triazoles / Q000009:adverse effects* / Q000493:pharmacokinetics; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D003577:Cytochrome P-450 Enzyme System; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D065819:Voriconazole